TEM
Tempus AI, Inc.
September 15, 2026 · intraday
- Rarity
- 1.25
- Peak move
- +10.62%
- Float cap
- $6.5B
Tempus AI is a healthcare technology company that provides AI-enabled diagnostics, including next-generation sequencing, PCR profiling, and anatomic and molecular pathology testing, to healthcare providers, life sciences companies, researchers, and other third parties. It also offers data and applications products that license de-identified clinical, molecular, and imaging data and provide analytics and clinical trial support to pharmaceutical and biotechnology companies.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
8 events · 0 from SEC or newswire · 0 timed with the moveanalyst_ratingTempus AI shares rose 3.9% to $64.63 in mid-day trading on September 15, with a Hold consensus and an average price target of $69.33 noted alongside the company's July 30 quarterly results.
- Key event
executive_remarkAt the Morgan Stanley 24th Annual Global Healthcare Conference, Tempus CEO Eric Lefkofsky said the company expects ~25% annual growth over the next decade and guided to $80M-$100M annual ASP lift from tumor-only xT CDx pricing ($2,923 to ~$4,500) plus $250M-$300M from liquid biopsy xF after expected H2 2027 FDA approval.
- Key event
executive_remarkTempus CEO Eric Lefkofsky said FDA approval of the main solid-tumor assay for tumor-only use should move it to ADLT pricing, adding $80M-$100M of incremental ASP lift, and a liquid biopsy approval expected in H2 2027 could add $250M-$300M in revenue.
executive_remarkTempus AI founder and CEO Eric Lefkofsky appeared on CNBC's 'The Exchange' to discuss AI's role in healthcare, advancing cancer research, and personalized vaccines.
- Key event
executive_remarkIn a Sept 14, 2026 media interview, Tempus AI founder/CEO Eric Lefkofsky backed Anthropic CEO Dario Amodei's call to slow AI model development, citing safety and capital efficiency, and praised Anthropic, OpenAI and SpaceX healthcare efforts.
government_contractTempus AI plans to use a nearly $9.5 million ARPA-H grant from HHS to build an autonomous AI clinical agent for treating heart failure patients as part of the ADVOCATE initiative, including a multi-center prospective clinical study.
product_launchTempus AI announced an initiative to build a research platform of 100,000 whole genomes linked to longitudinal clinical data, expanding toward one million genomes, with the initial dataset available via its Early Adopter Program and general availability planned for mid-2027.
peer_disclosurePersonalis shares traded above Tempus AI's $16.25-per-share all-stock acquisition offer announced July 20 after Personalis disclosed a higher verbal $17-per-share rival bid; Tempus holds a 12% stake and Merck agreed to vote its 13% stake in favor.